Furthermore, NAFLD affects CKD per se through lipoprotein metabolism and hepatokine secretion, and conversely, targeting the renal tubule by sodium–glucose cotransporter 2 (SGLT2) inhibitors can improve both CKD and NAFLD. The gene discussed is SLC5A2; the disease is chronic kidney disease.